

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 491 537 A8

(12)

CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)
INID code(s) 30

(51) Int Cl.7: **C07D 265/32**, A61K 31/5375,
A61P 9/00, A61P 9/10,
A61P 19/10, A61P 25/00,
A61P 25/28, A61P 27/02,
A61P 27/06, A61P 27/12,
A61P 37/02, A61P 43/00

(48) Corrigendum issued on:

30.03.2005 Bulletin 2005/13

(43) Date of publication:

29.12.2004 Bulletin 2004/53

(86) International application number:

PCT/JP2003/003910

(21) Application number: **03745432.9**

(87) International publication number:

WO 2003/082837 (09.10.2003 Gazette 2003/41)

(22) Date of filing: **27.03.2003**

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated Extension States:

AL LT LV MK

(72) Inventors:

- **NAKAMURA, Masayuki**
Kobe-shi, Hyogo 651-1141 (JP)
- **INOUE, Jun**
Kobe-shi Hyogo 654-0103 (JP)

(30) Priority: **29.03.2002 JP 2002097186**


(74) Representative:

von Kreisler, Alek, Dipl.-Chem. et al
Deichmannhaus am Dom,
Postfach 10 22 41
50462 Köln (DE)

(71) Applicant: **Senju Pharmaceutical Co., Ltd.**
Osaka-shi, Osaka 541-0046 (JP)

(54) **HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF**

(57) A compound represented by the following formula (I)



wherein R¹ and R² are each a lower alkyl group optionally having substituents, which has a calpain inhibitory activity, or a salt thereof is provided.

EP 1 491 537 A8

FIG. 1

